Emibetuzumab, formerly known as LY2875358, represents a unique medicinal approach in oncology, specifically targeting the HGF Receptor tyrosine enzyme. This recombinant immunoglobulin works by primarily connecting to https://www.targetmol.com/compound/emibetuzumab